Harmony Biosciences (HRMY) News Today $32.18 -1.67 (-4.93%) Closing price 04:00 PM EasternExtended Trading$33.19 +1.01 (+3.14%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMYMarch 3 at 1:15 PM | prnewswire.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Principal Financial Group Inc.Principal Financial Group Inc. boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 28.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 208,663 shares of tMarch 3 at 3:05 AM | marketbeat.comNew York State Common Retirement Fund Purchases 14,406 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)New York State Common Retirement Fund boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 30.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,878 sMarch 2 at 3:19 AM | marketbeat.comCantor Fitzgerald Has Negative View of HRMY FY2025 EarningsHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Harmony Biosciences in a research report issued to clients and investors on Wednesday, February 26th. Cantor Fitzgerald analyst C. DuncanMarch 1 at 8:30 AM | marketbeat.comEquities Analysts Issue Forecasts for HRMY FY2025 EarningsMarch 1 at 4:01 AM | americanbankingnews.comRhumbline Advisers Buys 16,537 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Rhumbline Advisers raised its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 18.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,588 shares of thMarch 1 at 3:09 AM | marketbeat.comHC Wainwright Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $70.00HC Wainwright decreased their target price on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Thursday.February 28 at 8:20 AM | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 287.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,061 shares of the company's stock after purchasing an adFebruary 28 at 3:58 AM | marketbeat.comHarmony Biosciences price target lowered to $70 from $75 at H.C. WainwrightFebruary 27, 2025 | markets.businessinsider.comHarmony Biosciences (NASDAQ:HRMY) Trading Down 8.2% - Here's WhyHarmony Biosciences (NASDAQ:HRMY) Shares Down 8.2% - Should You Sell?February 27, 2025 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Earns "Buy" Rating from Needham & Company LLCFebruary 27, 2025 | americanbankingnews.comIs Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now?February 26, 2025 | insidermonkey.comHarmony Biosciences price target raised to $33 from $31 at BofAFebruary 26, 2025 | markets.businessinsider.comHarmony Biosciences Holdings (HRMY) Receives a Rating Update from a Top AnalystFebruary 26, 2025 | markets.businessinsider.comHarmony Biosciences (HRMY) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | msn.comHarmony Biosciences Holdings Inc (HRMY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...February 26, 2025 | finance.yahoo.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Denali Advisors LLCDenali Advisors LLC grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 102.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,314 shares of the company's stock afFebruary 26, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 25, 2025 | seekingalpha.comHarmony Biosciences reports Q4 EPS $1.08, consensus 82cFebruary 25, 2025 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Harmony Biosciences (NASDAQ:HRMY)Needham & Company LLC reiterated a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday.February 25, 2025 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Estimates By $0.34 EPSHarmony Biosciences (NASDAQ:HRMY - Get Free Report) issued its earnings results on Tuesday. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.34. The company had revenue of $201.30 million for the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm's revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 EPS.February 25, 2025 | marketbeat.comHarmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development ProgramsFebruary 25, 2025 | businesswire.comAllspring Global Investments Holdings LLC Reduces Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Allspring Global Investments Holdings LLC trimmed its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 57.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,306February 25, 2025 | marketbeat.comEarnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Reports Q4 2024 ResultFebruary 25, 2025 | finance.yahoo.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by HealthInvest Partners ABHealthInvest Partners AB lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 20.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 120,501 shares of the company's stock after selling 31February 24, 2025 | marketbeat.comFY2025 EPS Estimates for HRMY Decreased by Cantor FitzgeraldHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Thursday, February 20th. Cantor Fitzgerald analyst C. Duncan now forecasts tFebruary 22, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Alberta Investment Management CorpAlberta Investment Management Corp raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 44.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,600 shFebruary 22, 2025 | marketbeat.comMizuho Cuts Harmony Biosciences (NASDAQ:HRMY) Price Target to $42.00Mizuho cut their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating for the company in a report on Thursday.February 21, 2025 | marketbeat.comHussman Strategic Advisors Inc. Buys 21,000 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Hussman Strategic Advisors Inc. increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 33.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 84,000 shares of the company's stock after purchasing an additional 21,February 21, 2025 | marketbeat.comNeedham & Company LLC Has Lowered Expectations for Harmony Biosciences (NASDAQ:HRMY) Stock PriceFebruary 21, 2025 | americanbankingnews.comHarmony Biosciences price target lowered to $42 from $52 at MizuhoFebruary 20, 2025 | markets.businessinsider.comHarmony Biosciences (NASDAQ:HRMY) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of Harmony Biosciences in a report on Wednesday.February 20, 2025 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Shares Gap Down After Analyst DowngradeHarmony Biosciences (NASDAQ:HRMY) Shares Gap Down Following Analyst DowngradeFebruary 20, 2025 | marketbeat.comNeedham & Company LLC Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $50.00Needham & Company LLC lowered their price target on Harmony Biosciences from $52.00 to $50.00 and set a "buy" rating for the company in a report on Wednesday.February 20, 2025 | marketbeat.comHarmony Biosciences (HRMY) to Release Earnings on ThursdayHarmony Biosciences (NASDAQ:HRMY) will be releasing earnings before the market opens on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=372794)February 20, 2025 | marketbeat.comHarmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping DisorderFebruary 19, 2025 | benzinga.comHarmony Biosciences stock tumbles after FDA setbackFebruary 19, 2025 | au.investing.comHarmony Biosciences receives refusal to file letter from FDA for pitolisantFebruary 19, 2025 | markets.businessinsider.comHarmony Biosciences's sleep disorder treatment gets FDA Refuse to File letterFebruary 19, 2025 | msn.comHarmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic HypersomniaFebruary 19, 2025 | businesswire.comHarmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025February 19, 2025 | businesswire.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Recommendation of "Buy" from AnalystsShares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have earned a consensus recommendation of "Buy" from the nine ratings firms that are presently covering the stock, Marketbeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The avFebruary 16, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest UpdateHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,770,000 shares, a drop of 31.8% from the January 15th total of 5,530,000 shares. Approximately 9.3% of the company's stock are sold short. Based on an average daily trading volume, of 540,800 shares, the short-interest ratio is presently 7.0 days.February 15, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc (HRMY): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | msn.comFY2024 EPS Estimates for HRMY Boosted by Cantor FitzgeraldHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2024 earnings estimates for Harmony Biosciences in a research report issued on Tuesday, February 11th. Cantor Fitzgerald analyst C. Duncan now expects that the company will posFebruary 12, 2025 | marketbeat.comDeutsche Bank Initiates Coverage of Harmony Biosciences Holdings (HRMY) with Buy RecommendationFebruary 12, 2025 | msn.comDeutsche Bank sets Harmony Biosciences stock Buy rating, $55 targetFebruary 11, 2025 | msn.comHarmony Biosciences initiated with a Buy at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comHarmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from Analysts at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research report on Tuesday. They issued a "buy" rating and a $55.00 price target on the stock.February 11, 2025 | marketbeat.comPolaris Capital Management LLC Has $2.01 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Polaris Capital Management LLC boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 29.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,300 shares of the coFebruary 11, 2025 | marketbeat.com Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Media Mentions By Week HRMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRMY News Sentiment▼0.730.71▲Average Medical News Sentiment HRMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRMY Articles This Week▼316▲HRMY Articles Average Week Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Telix Pharmaceuticals Limited American Depositary Shares News Revolution Medicines News BridgeBio Pharma News Legend Biotech News Axsome Therapeutics News Blueprint Medicines News Cytokinetics News Nuvalent News Elanco Animal Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRMY) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRMY Stock Alerts